Bebtelovimab is a neutralizing anti-SARS-CoV-2 monoclonal antibody that retained activity against early Omicron variants but is not expected to neutralize the later and now predominant Omicron subvariants BQ. 1 and BQ. 1.1; therefore, effective November 30, 2022, bebtelovimab is not authorized for use in the US (see FDA Announces Bebtelovimab is Not Currently Authorized in Any US Region).